Repligen falls 7.7% after completing acquisition of BioLife

What happened

Repligen (RGEN) fell 7.7% on October 6, 2026, after the company completed its previously disclosed acquisition of BioLife Solutions, a maker of equipment and support services used in cell and gene therapy processing, according to GlobeNewsWire. The stock closed at $174.86, trading at 1.5 times its 20-day average. The move came as a largely company-specific event: the S&P 500 rose 0.6% on the day while the healthcare sector median fell 1.8%, making the stock’s decline 6.0 percentage points worse than the sector median.

How big was the move

The $174.86 close represented a move that was 2.5 times a typical daily move for this stock. Over the last five sessions the stock fell 10.1% while the S&P 500 rose 1.9% over the same period. Trading volume ran at 1.5 times its 20-day average, and the stock’s market sensitivity is a beta of 1.40, meaning the stock tends to move more than the market. In the past five years the stock had 16 sessions with a decline of at least 7.7%; twenty trading days later the median result was a decline of 1.0% and 7 of the 16 were higher. Market-data reports noted notable intraday pricing on October 5 and October 6, 2026, with a $189.50 print after a 4.3% rise on October 5 and the $174.86 close after a 7.7% drop on October 6, according to GuruFocus.

The technical picture

Technically, the stock remained in an established uptrend. It was 1.8% above its 50-day moving average and 21.6% above its 200-day moving average, with the 50-day average above the 200-day average. The shares had been above the 200-day average for 50 consecutive trading days. Shorter-term measures showed it was 2.9% below its 20-day moving average and the Relative Strength Index (14 days) was 47, in a neutral range between 30 and 70. The shares sat 12.1% below the 52-week high. Momentum readings showed a rise of 4.3% over one month, 27.3% over three months and 17.6% over one year, which was 1.1 percentage points ahead of the S&P 500. Volatility was 50% annualized over 60 days, lower than 53% of its own readings over five years.

Fundamentals and valuation

For the four quarters through June 30, 2026, revenue was $785.1 million, which grew 16.5% from a year earlier and followed growth of 17.4% one quarter earlier. Diluted earnings per share for that period were $0.73, which rose 812.5% from a year earlier. The company has improved margins: gross margin was 51.1% (a year earlier: 44.3%), operating margin was 8.3% (a year earlier: 3.5%), and free-cash-flow margin was 14.1%. Return on invested capital was 1.8% and the balance sheet showed net debt of 0.7 times EBITDA. Share count over one year increased by 0.3%.

Those operating gains sit against a very rich valuation. The stock trades at 239.5 times trailing earnings, a level higher than 76% of its own readings over the past five years (five-year median: 126.5 times earnings). Price to forward earnings is 84.9 times expected earnings and free-cash-flow yield is 1.1%. PromtFinance sector-ranked scores place Value at 52 (Neutral), Growth at 55 (Neutral), Quality at 79 (Positive), Momentum at 75 (Positive), Revisions at 75 (Positive), and Stability at 62 (Neutral). The combination of rapid recent margin gains and a stretched valuation frames the risk-reward picture for investors.

Earnings and analyst expectations

Repligen’s last report, on July 28, 2026, showed earnings per share of $0.54 against $0.45 expected, 20.8% above estimates. That was the fourth consecutive quarter beating estimates, with an average surprise over the last four reports of 17.0% above estimates. Typical two-day reactions after recent reports were a rise of 3.4%. The next report was scheduled for November 3, 2026. Analyst coverage comprises 24 analysts, with 92% rating the stock Buy or above and a consensus rating of Buy. The consensus price target is $162.43, which is 7.1% below the closing price on October 6, 2026.

What to watch

• November 3, 2026: next earnings report date
• Integration progress and any guidance updates following completion of the BioLife acquisition, announced October 6, 2026
• Short-term price action relative to the 50-day moving average at 1.8% above its 50-day moving average and the 200-day at 21.6% above its 200-day moving average
• Any revisions to analyst estimates given the company’s four consecutive quarters of beats and an average surprise of 17.0% above estimates
• Trading volume trends after the 1.5 times its 20-day average session and whether volatility, currently 50% annualized over 60 days, changes materially